Benzinga | Nov 4, 2021 09:40AM EDT

Credit Suisse Maintains Outperform on Amedisys, Raises Price Target to $205

Credit Suisse analyst Jonathan Yong maintains Amedisys (NASDAQ:AMED) with a Outperform and raises the price target from $192 to $205.